Background. Large cell neuroendocrine carcinoma is a recently recognized histologic entity whose clinical features and optimal treatment have not yet been well defined and are still being assessed. We report our retrospective assessment of cases of large cell neuroendocrine carcinoma observed from 1989 to 1999 in terms of survival.
Material and Methods
In the period from 1989 to 1999, 1,530 patients with primitive pulmonary neoplasm underwent surgical intervention in our unit. Routine hematoxylin and eosinstained sections of these patients were reviewed by a single pathologist. In 113 (7.3%) of the tumors that presented NE morphology immunohistochemistry was performed to confirm the NE phenotype. Primary anti-bodies against chromogranin A (BIOGENEX, monoclonal 1:500; BIOGENEX Laboratories, Inc, San Ramon, CA) and synaptophysin (BIOGENEX, monoclonal 1:100) were used. The sections with NE morphology that expressed one immunohistochemical marker in at least 10% of tumor cells were considered positive. The following histologic diagnoses were made: typical carcinoid (n ϭ 23), atypical carcinoid (n ϭ 2), LCNEC (n ϭ 53), SCLC (n ϭ 22), large cell carcinomas with NE morphology (n ϭ 13).
A diagnosis of LCNEC was made when all WHO classification criteria were present in the section.
All patients underwent a preoperative computed tomography scan of the chest, adrenal gland, liver, and brain, bone scanning, fibrobronchoscopy and biopsy (endo/transbronchial, transthoracic) when possible. The stage of disease was based on the TNM classification using the International Union Against Cancer (UICC) staging system [9] . All patients underwent surgery and had no local macroscopic or microscopic neoplastic residue.
Statistical analysis was carried out using an SPSS package (SPSS, Chicago, IL). The overall survival of the patients was calculated by means of the Kaplan-Meier methods [10] . Comparison survival curves between patients with LCNEC and patients with SCLC was performed by log-rank tests. In all cases, the neoplasm presented an NE appearance characterized by organoid nesting, palisading, or trabecular growth. The cancer cells were medium-to-large size, with large cytoplasm, atypical nucleus, and often evident nucleoli. There were numerous mitoses (Ͼ 10 per 10 high-power field, often Ͼ 100), and tumoral necrosis was abundant in all cases (Fig 1) .
Results

Of
The NE phenotype was confirmed in all cases by immunohistochemical positivity for chromogranin A (Fig  2) or synaptophysin in at least 10% of neoplastic cells.
Clinical follow-up lasted 12 years with a median fol- (Fig 3) . The actuarial survival of accurately staged, stage I patients at 5 years was 27% (Fig 4) . (Fig 3) . The actuarial survival of accurately staged, stage I patients at 5 years was 9% (Fig 4) . The actuarial survival of patients in stage II and III was 0% at 5 years (Figs 5, 6 ).
The actuarial survival of patients with LCNEC and SCLC was compared for all stages. Not significant differ- 
Comment
The classification of NE tumors has undergone numerous changes over the years, thereby causing diagnostic difficulties for pathologists. To these difficulties can be added the still not clearly defined therapeutic course to be taken. Large cell neuroendocrine carcinoma differs from low grade and medium grade NE forms in terms of its greater quantity of mitosis (Ͼ 10 per 10 high-power field) and abundant necrosis, and from SCLC exclusively in terms of its cytologic characteristics. There are four types of large cell tumors, each determined by its morphology and neuroendocrine differentiation: (1) LCNEC with a morphologic appearance and NE differentiation under electron microscope or immunohistochemistry; (2) large cell carcinoma with NE differentiation that does not have an NE carcinoma morphology but tests positive immunohistochemicaly or under electron microscope for its NE differentiation; (3) large cell carcinomas with NE morphology that have an NE morphology but not the neuroendocrine phenotype as seen under an electron microscope or immunohistochemically; (4) classic large cell carcinomas that have neither NE morphology nor differentiation. The distinction therefore from large cell carcinoma depends essentially on the absence in this last of an NE morphologic appearance under light microscopy and on the absence of a NE differentiation under electron microscope or immunohistochemically. Large cell neuroendocrine carcinoma differs from NSCLC tumors with NE immunophenotype (10% to 20% of NSCLC), known as NSCLC with NE differentiation (NSCLC-ND) due to the absence in the latter of a NE morphology under light microscopy. The term "combined LCNEC" should be used for those LCNEC that have components of adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
Diagnosing LCNEC can be particularly difficult for pathologists due to the overlapping of the abovedescribed entities, and a differential diagnosis with SCLC is particularly difficult [12] . Other morphometric studies have shown a significant overlapping between the nuclear dimensions of LCNEC and SCLC [13] .
A preoperative diagnosis of LCNEC was not made for any patient. It is difficult to perform transbronchial biopsy on these usually peripheral tumors and cytology with immunohistochemistry on fine needle biopsy is not sufficient to accurately diagnose these tumors [7] . In our series, the patients with LCNEC represented 3.5% of all patients undergoing surgery for pulmonary neoplasm. These results are slightly higher than those reported in the literature [5, 14] . Overall survival of patients with LCNEC at 1 year (60.4%), at 3 years (27.5%), and at 5 years (21.2%) was lower than usually seen for NSCLC, and more similar to that for SCLC (in our series overall survival was 68.1% for 1 year, 18.1% for 3 years, and 4.5% The 5-years actuarial survival of patients with LCNEC in stage I (27%) was particularly low when compared with the literature [8] . Affecting this is predominantly the poor survival rate recorded for stage IB (9.5%). The interval patients were free of disease was 16.9 months on average, with recurrence in 70.8% of cases. The recurrence rate in the literature is 57% [15] . In a series of patients described by Maziè res [7] , the response to cisplatin-based chemotherapy was 20% and partial. This pathology is therefore to be considered as having a high grade of malignancy. Induction chemotherapy was not carried out in our series of patients. Given the extreme histologic, immunohistochemical, and molecular similarity [16] between LCNEC and SCLC and the fact that LCNEC's clinical outcome is more similar to that of SCLC than to that of NSCLC, we wonder whether pathologists' interpretive difficulty has a real clinical effect and whether it might not be better to define a new therapeutic course that differs from that for NSCLC, for example one that foresees a combined modality treatment for each clinical case even when chemosensitivity seems lower than that in SCLC [7] , with resistance attributed to the high frequency of MDR 1 gene expression [17] . In NSCLC patients NE differentiation appears to be an independent prognostic factor in terms of chemotherapy response [18] . Few studies have been done on adjuvant chemotherapy and these do not demonstrate improved survival rates [15] . The presence of lymph node involvement, mitotic rate, or the presence of molecular anomalies such as p53 and Bcl-2 do not seem to be correlated to clinical outcome [7] . Adjuvant radiotherapy seems to be effective in controlling the disease locally [7] . Some authors [14] have suggested classifying LCNEC and SCLC in one group called "high-grade malignant neuroendocrine tumors" and using this biological information to define the treatment program.
In conclusion, LCNEC represents a subtype of NE tumor that is highly malignant and whose poor prognosis is more similar to that for SCLC than to that for NSCLC. While optimal treatment remains to be defined, the criteria applied to NSCLC are currently used. In our opinion a combined modality treatment approach that uses new chemotherapy regimens should be explored.
